This is unpublished

Judith
Tsui
MD
MPH

she, her, they
Faculty
Ambulatory
Pinned
Academic
Professor, Medicine
Professional
Director, UW Medical Student Addiction Research Program (MedStAR)
Director, UW/Fred Hutch Center for AIDS Research (CFAR) Substance Use Scientific Working Group
Sites of Practice
Adult Medicine Clinic, HMC

biography

Dr. Judith Tsui is a Professor of Medicine at the University of Washington, based at Harborview Medical Center. She is also Adjunct Professor in the Health Systems and Population Health Department in the School of Public Health. She is a board-certified internist who is also a diplomate in Addiction Medicine through the American Board of Addiction Medicine since 2013. She is PI/Director of the NIH/NIDA R25-funded UW Medical Student Addiction Research (“MedStAR”) Program since 2020 and MPI of an NIH/NIDA-funded T32 program based in the Department of Health Systems and Population Health at the School of Public Health (“Training in Equity and Structural Solutions in Addictions” [TESSA]). Since 2023 she is the Director of the UW/Fred Hutch Center for AIDS Research Substance Scientific Working Group.

Education & Training

  • BA, Princeton University, Princeton, NJ (1991)
  • MD, New York University, New York, NY (1997)
  • Residency, Oregon Health Sciences University, Portland, OR (1998–2000)
  • MPH, Rollins School of Public Health, Emory University, Atlanta, GA (2004)
  • Fellow, University of California, San Francisco, CA (2004–2008)

Honors

  • UW Department of Medicine Gender Equity Award (2023)
  • Nominee, UW School of Medicine Excellence in Mentoring Women Faculty Award (2020)
  • Outstanding Research Mentor Award, UW Medical School Class of 2017 (2019)
  • Research paper selected for NIDA “Director’s Report” by Dr. Nora Volkow (2016)
  • Research paper selected for NIDA “Director’s Report” by Dr. Nora Volkow (2015)
  • Internal Medicine Wards Attending Teaching Award, Emory University School of Medicine (2002)
  • Stanley Foundation Research Award, NYU School of Medicine (1994)
  • Magna Cum Laude, Princeton University (1991)

research

Dr. Tsui’s overarching goal is to improve care delivery and health outcomes for persons who use drugs. Current research is focused on innovative health service delivery interventions to expand access, and improve adherence, to potentially life-saving medications for persons who use drugs, including medications for opioid use disorder, HCV, and PrEP. Additionally, she has conducted research on substance use, pain, and opioid prescribing for persons living with HIV. She is also is actively involved in leading training programs to create the next generation of Addiction Medicine-trained physicians who are committed to expanding evidence-based care for persons with substance use disorders.

Dr. Tsui mentors medical students, residents, fellows, and graduate students who are interested in health services and clinical research on substance use disorders, HIV prevention,  HCV elimination, and the integration of addiction services and primary care. She publishes in and is a regular reviewer/editor/commentator for peer-reviewed journals.

Dr. Tsui welcomes emailed queries about research opportunities.

Research Activities and Current Funding

The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States

Role: Principal Investigator
2R25DA050985-06

Training in Equity and Structural Solutions in Addictions (TESSA)

Role: Multiple Principal Investigator
T32DA057920

A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model to Cure Hepatitis C Among Persons Who Use Drugs with Housing

Role: Multiple Principal Investigator (Contact)
R01DA062638

Implementing HIV screening and prevention in low-barrier Office-Based Opioid Treatment (OBOT) programs to end the HIV epidemic

Role: Multiple Principal Investigator (Contact)
R01DA065037

Improving the transition to outpatient opioid use disorder treatment through patient navigation plus remote mHealth adherence support for patients initiated on buprenorphine in the hospital

Role: Multiple Principal Investigator (Contact)
R01DA065598

ARCH REACH: ARCH Center for Research at the intersection of Equity, Alcohol, Community and HIV

Role: Co-Investigator / Component Study PI
1P60AA032166-01

Adapting and scaling patient-centered collaborative care delivery models to offer treatment for substance use disorders and hepatitis C

Role: Principal Investigator
K24DA066945

Selected Previous Funding

Rural Comorbidity and HIV Consequences of Opioid use Research and Treatment Initiative (Rural cohort)

Role: Multiple Principal Investigator
1U24DA048538

Patient Navigator plus Remote mHealth Adherence Support with Incentives to Improve Linkage and Retention among Hospitalized Patients with Opioid and Methamphetamine Use who Initiate Buprenorphine

Role: Principal Investigator
1R34DA057609

Clinical Trials Network: CTN-0110 Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB)

Role: Project/Subaward Principal Investigator
UG1DA020024

HRSA UW Addiction Medicine Fellowship

Role: Associate Program Director, Co-Investigator
1T25HP376280100
Addiction Medicine Fellowship

Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV among Persons Who Inject Drugs

Role: Principal Investigator
1R34DA047660

Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol

Role: Multiple Principal Investigator
UH2AA026193

Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program

Role: Multiple Principal Investigator
1R41DA053081

Patient-Centered Models of HCV Care for People who Inject Drugs

Role: Subaward Principal Investigator
HPC-1503-28122

Development and Evaluation of Effectiveness of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine

Role: Multiple Principal Investigator
R44DA044053

publication highlights

  • Tsui JI, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, Young AM, Cooper HLF, Friedmann PD, Stopka TJ, de Gijsel D, Miller WC, Go VF, Westergaard R, Brown R, Seal DW, Zule WA, Feinberg J, Smith GS, Mixson LS, Fredericksen R, Crane HM, Delaney JA; Rural Opioid Initiative Consortium. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend. 2023 Aug 2;250:110911. doi: 10.1016/j.drugalcdep.2023.110911. Epub ahead of print. PMID: 37549545.
  • Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Ninburg M, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug Alcohol Depend Rep. 2023 Dec 23;10:100213. doi: 10.1016/j.dadr.2023.100213. PMID: 38261893; PMCID: PMC10796962.
  • Tsui JI, Rossi SL, Cheng DM, Bendiks S, Vetrova M, Blokhina E, Winter M, Gnatienko N, Backonja M, Bryant K, Krupitsky E, Samet JH. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLoS One. 2024 Feb 26;19(2):e0297948. doi: 10.1371/journal.pone.0297948. PMID: 38408060; PMCID: PMC10896547.
  • James JR, Mohabir AM, Simon CB, Cole A, Huriaux E, Stockton J, Rouvere J, Tsui JI. Hepatitis C care delivery practices among buprenorphine prescribers and non-prescribers: results from a survey of Washington state primary care providers. Addict Sci Clin Pract. 2025 Sep 24;20(1):75. doi: 10.1186/s13722-025-00603-9. PMID: 40993801; PMCID: PMC12462307.
  • Leyde S, Tilhou AS, Tsui JI. Methamphetamine Use Disorder. JAMA. 2025 Oct 7;334(13):1192-1193. doi: 10.1001/jama.2025.12007. PMID: 40900575.
  • Tsui JI, Bhatraju EP, Hallgren KA, Rhew IC, Samet JH. High-dose Buprenorphine Treatment in the Setting of Fentanyl. JAMA Netw Open. 2025 Aug 1;8(8):e2528119. doi: 10.1001/jamanetworkopen.2025.28119. PMID: 40839262.
  • Tsui JI, Austin EJ, Dunn JA, Gojic AJ, Bhatraju EP, Darnton J, Grekin P, Soth S, Woolworth S, Williams EC, Hallgren KA. Acceptability of and Implementation Supports for Video Directly Observed Treatment to Enhance Methadone Dosing Flexibility in a Multisite Opioid Treatment Program: Qualitative Rapid Needs Assessment Study. JMIR Form Res. 2026 Jan 12;10:e84162. doi: 10.2196/84162. PMID: 41525682.
  • Iacobelli NP, Estrella L, Owens MD, Bhatraju EP, Gojic AJ, Kennedy D, Chander G, Tsui JI. "You're doing it because your freedom is on the line": a qualitative study exploring how people who use opioids and methamphetamine navigate legal involvement and carceral treatment for substance use disorder. Harm Reduct J. 2026 Jan 17. doi: 10.1186/s12954-025-01378-7. Epub ahead of print. PMID: 41547813.
  • Zinsli KA, Mixson LS, Delaney JA, Feinberg J, Stopka TJ, Seal DW, Smith GS, Pho MT, Wu EL, Jenkins W, Cooper HLF, Young AM, Khoury D, Friedmann PD, Miller WC, Go VF, Korthuis PT, Spencer H, Westergaard RP, Tsui JI. The Association Between Receiving Medications for Opioid Use Disorder and Human Immunodeficiency Virus Testing: Findings From the Rural Opioid Initiative. J Addict Med. 2026 Mar 24. doi: 10.1097/ADM.0000000000001671. Epub ahead of print. PMID: 41875202.
  • Bhatraju EP, Gregorich OL, Hallgren KA, Williams EC, Chander G, Tsui JI. "You're Hoping for the Best, but Preparing for the Worst": Discussions of Starting Buprenorphine in the Context of Fentanyl Use with Clinicians and People Who Use Fentanyl. J Gen Intern Med. 2026 Mar 30. doi: 10.1007/s11606-026-10365-y. Epub ahead of print. PMID: 41912941.
  • Bhatraju EP, Zinsli KA, Kennedy DN, Gojic AJ, Iles-Shih M, Merrill JO, Speaker EC, Samet JH, Hallgren KA, Tsui JI. Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026;9(10):e2638542. doi:10.1001/jamanetworkopen.2026.38542.

 

Cited in the Popular Press